Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-05-02 | 2025-04-21 |
| Drug Identification Number | 02508419 | 02508419 |
| Brand name | HYOSCINE BUTYLBROMIDE INJECTION BP | HYOSCINE BUTYLBROMIDE INJECTION BP |
| Common or Proper name | HYOSCINE BUTYLBROMIDE | HYOSCINE BUTYLBROMIDE |
| Company Name | OMEGA LABORATORIES LIMITED | OMEGA LABORATORIES LIMITED |
| Ingredients | HYOSCINE BUTYLBROMIDE | HYOSCINE BUTYLBROMIDE |
| Strength(s) | 20MG | 20MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 10 x 1 mL vial / fiole | 10 x 1 mL |
| ATC code | A03BB | A03BB |
| ATC description | BELLADONNAAND DERIVATIVES, PLAIN | BELLADONNAAND DERIVATIVES, PLAIN |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-05-21 | 2025-04-21 |
| Actual start date | ||
| Estimated end date | 2025-07-31 | 2025-07-31 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | We are currently collaborating with Health Canada’s Drug Shortages Unit to mitigate any market impact. | We are currently collaborating with Health Canada’s Drug Shortages Unit to mitigate any market impact. |
| Health Canada comments |